A collection of publications and data presentations relevant to Reata's development programs
Kidney Effects in the MOXIe Trial: Presentation at ERA-EDTA 2020
Friedreich’s Ataxia (FA) is a rare, progressive, and debilitating genetic disorder with no approved treatments. Kidney function was assessed in patients with Friedreich’s ataxia in Part 2 of MOXIe, a Phase 2 international, multicenter, double-blind, randomized, placebo-controlled study of omaveloxolone in FA.
We use cookies to offer you a better browsing experience, analyze site usage, and improve the website. By clicking “Accept Cookies”, you expressly agree to our use of cookies in accordance with the use of cookies section of our Privacy Notice. If you wish to prevent our use of cookies, you can opt-out below.